Management of postmenopausal osteoporosis

Annual Review of Medicine

Volumn 66, Issue , 2015, Pages 329-342

  Andreopoulou, Panagiota ^a   Bockman, Richard S ^a,b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

bone microarchitecture; combination therapy; fracture risk

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; ESTROGEN; GESTAGEN; MONOCLONAL ANTIBODY; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE MASS; BONE STRUCTURE; CLINICAL ASSESSMENT TOOL; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN THERAPY; FRACTURE RISK ASSESSMENT TOOL; FRAGILITY FRACTURE; HIGH RISK PATIENT; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; TRABECULAR BONE; TRABECULAR BONE SCORE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PHOTON ABSORPTIOMETRY;

ABSORPTIOMETRY, PHOTON; ANABOLIC AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; CALCIUM; DIPHOSPHONATES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; RISK ASSESSMENT; TERIPARATIDE; TOMOGRAPHY, X-RAY COMPUTED; VITAMIN D;

EID: 84921395889     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-070313-022841     Document Type: Article

References (100)

1. Lewiecki EM, Gordon CM, Baim S, et al. 2008. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone 43:1115-21
2. Eur. Found. Osteoporos. Bone Dis. 2001. Osteoporosis prevention, diagnosis, and therapy. Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. NIH Consensus. JAMA 285:78S
3. Stone KL, Seeley DG, Lui LY, et al. 2003. BMD at multiple sites and risk of fracture of multiple types: long-Term results from the Study of Osteoporotic Fractures. J. Bone Miner. Res. 18:1947-54
4. Johnell O, Kanis JA, Oden A, et al. 2005. Predictive value of BMD for hip and other fractures. J. Bone Miner. Res. 20:1185-94
5. Compston J. 2009. Monitoring bone mineral density during antiresorptive treatment for osteoporosis. BMJ 338:b1276
6. Schousboe JT, Vokes T, Broy SB, et al. 2008. Vertebral fracture assessment: the 2007 ISCD official positions. J. Clin. Densitom. 11:92-108
7. BlakeGM, Chinn DJ, Steel SA, et al. 2005. A list of device-specific thresholds for the clinical interpretation of peripheral x-ray absorptiometry examinations. Osteoporos. Int. 16:2149-56
8. Kanis JA, Johnell O, Oden A, et al. 2008. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 19:385-97
9. Kanis JA, Oden A, Johnell O, et al. 2007. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos. Int. 18:1033-46
10. Leslie WD, Lix LM, Johansson H, et al. 2010. Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J. Bone Miner. Res. 25:2350-58
11. Hippisley-Cox J, CouplandC. 2009. Predicting risk of osteoporotic fracture inmen andwomen in England andWales: prospective derivation and validation of QFractureScores. BMJ 339:b4229
12. Kanis JA, Johnell O, De Laet C, et al. 2002. International variations in hip fracture probabilities: implications for risk assessment. J. Bone Miner. Res. 17:1237-44
13. Leslie WD, Lix LM, Johansson H, et al. 2012. Does osteoporosis therapy invalidate FRAX for fracture prediction?. J. Bone Miner. Res. 27:1243-51
14. Leslie WD, Lix LM, Johansson H, et al. 2011. Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos. Int. 22:839-47
15. Wainwright SA, Marshall LM, Ensrud KE, et al. 2005. Hip fracture in women without osteoporosis. J. Clin. Endocrinol. Metab. 90:2787-93
16. Boutroy S, Bouxsein ML, Munoz F, Delmas PD. 2005. In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J. Clin. Endocrinol. Metab. 90:6508-15
17. Genant HK, Engelke K, Prevrhal S. 2008. Advanced CT bone imaging in osteoporosis. Rheumatology 47(Suppl. 4):iv9-16
18. Krug R, Carballido-Gamio J, Banerjee S, et al. 2008. In vivo ultra-high-field magnetic resonance imaging of trabecular bone microarchitecture at 7 T. J. Magn. Reson. Imaging 27:854-59
19. PooleKE, TreeceGM, Mayhew PM, et al. 2012. Cortical thickness mapping to identify focal osteoporosis in patients with hip fracture. PLOS ONE 7:e38466
20. Center JR, Nguyen TV, Pocock NA, et al. 1998. Femoral neck axis length, height loss and risk of hip fracture in males and females. Osteoporos. Int. 8:75-81
21. Naylor KE, McCloskey EV, Eastell R, Yang L. 2013. Use of DXA-based finite element analysis of the proximal femur in a longitudinal study of hip fracture. J. Bone Miner. Res. 28:1014-21
22. Pothuaud L, BenhamouCL, Porion P, et al. 2000. Fractal dimension of trabecular bone projection texture is related to three-dimensional microarchitecture. J. Bone Miner. Res. 15:691-99
23. Hans D, Barthe N, Boutroy S, et al. 2011. Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae. J. Clin. Densitom. 14:302-12
24. Silva BC, Walker MD, Abraham A, et al. 2013. Trabecular bone score is associated with volumetric bone density and microarchitecture as assessed by central QCT and HRpQCT in Chinese American and white women. J. Clin. Densitom. 16:554-61
25. Silva BC, Leslie WD, Resch H, et al. 2014. Trabecular bone score: a noninvasive analytical method based upon the DXA image. J. Bone Miner. Res. 29:518-30
26. Hans D, Goertzen AL, Krieg MA, Leslie WD. 2011. Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J. Bone Miner. Res. 26:2762-69
27. Briot K, Paternotte S, Kolta S, et al. 2013. Added value of trabecular bone score to bone mineral density for prediction of osteoporotic fractures in postmenopausal women: the OPUS study. Bone 57:232-36
28. Cormier C, Lamy O, Poriau S. 2012. TBS in Routine Medical Practice: Proposals of Use. Plan-les-Ouates, Switz.: Medimaps Group. http://www.medimapsgroup.com/upload/MEDIMAPS-UK-WEB.pdf
29. Pothuaud L, Barthe N, Krieg MA, et al. 2009. Evaluation of the potential use of trabecular bone score to complement bone mineral density in the diagnosis of osteoporosis: a preliminary spine BMD-matched, case-control study. J. Clin. Densitom. 12:170-76
30. Winzenrieth R, Dufour R, Pothuaud L, Hans D. 2010. A retrospective case-control study assessing the role of trabecular bone score in postmenopausal Caucasian women with osteopenia: analyzing the odds of vertebral fracture. Calcif. Tissue Int. 86:104-9
31. Rabier B, Heraud A, Grand-Lenoir C, et al. 2010. Amulticentre, retrospective case-control study assessing the role of trabecular bone score (TBS) in menopausal Caucasian women with low areal bone mineral density (BMDa): analysing the odds of vertebral fracture. Bone 46:176-81
32. KruegerD, Fidler E, Libber J, et al. 2014. Spine trabecular bone score subsequent to bonemineral density improves fracture discrimination in women. J. Clin. Densitom. 17:60-65
33. Leib E, Winzenrieth R, Aubry-Rozier B, HansD. 2014. Vertebralmicroarchitecture and fragility fracture in men: a TBS study. Bone 62:51-55
34. Boutroy S, HansD, Sornay-Rendu E, et al. 2013. Trabecular bone score improves fracture risk prediction in non-osteoporotic women: the OFELY study. Osteoporos. Int. 24:77-85
35. Krieg MA, Aubry-Rozier B, Hans D, Leslie WD. 2013. Effects of anti-resorptive agents on trabecular bone score (TBS) in older women. Osteoporos. Int. 24:1073-78
36. Senn C, Gunther B, Popp AW, et al. 2014. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study. Osteoporos. Int. 25:1945-51
37. Kolta S, Briot K, Fechtenbaum J, et al. 2014. TBS result is not affected by lumbar spine osteoarthritis. Osteoporos. Int. 25:1759-64
38. Leslie WD, Krieg MA, Hans D. 2013. Clinical factors associated with trabecular bone score. J. Clin. Densitom. 16:374-79
39. Lamy O, Krieg MA, Stoll D, et al. 2013. What is the performance in vertebral fracture discrimination by bone mineral density (BMD), microarchitecture estimation (TBS), and FRAX in stand-Alone, combined or adjusted approaches: the OsteoLaus Study. Bone Abstr. 1:PP339
40. Tang BM, Eslick GD, Nowson C, et al. 2007. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-Analysis. Lancet 370:657-66
41. BollandMJ, Avenell A, Baron JA, et al. 2010. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-Analysis. BMJ 341:c3691
42. WangL, Manson JE, SongY, SessoHD.2010. Systematic review: VitaminDand calcium supplementation in prevention of cardiovascular events. Ann. Intern. Med. 152:315-23
43. Lewis JR, Calver J, Zhu K, et al. 2011. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up. J. Bone Miner. Res. 26:35-41
44. Bockman RS, Zapalowski C, Kiel DP, Adler RA. 2012. Commentary on calcium supplements and cardiovascular events. J. Clin. Densitom. 15:130-34
45. Langsetmo L, Berger C, Kreiger N, et al. 2013. Calcium and vitamin D intake and mortality: results from the Canadian Multicentre Osteoporosis Study (CaMos). J. Clin. Endocrinol. Metab. 98:3010-18
46. Anderson GL, Limacher M, AssafAR, et al. 2004. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: theWomen's Health Initiative randomized controlled trial. JAMA 291:1701-12
47. Ross AC, Manson JE, Abrams SA, et al. 2011. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J. Clin. Endocrinol. Metab. 96:53-58
48. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. 2005. Fracture prevention with vitamin D supplementation: a meta-Analysis of randomized controlled trials. JAMA 293:2257-64
49. Chapuy MC, Arlot ME, Duboeuf F, et al. 1992. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N. Engl. J. Med. 327:1637-42
50. Rossouw JE, AndersonGL, Prentice RL, et al. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-33
51. Cauley JA, Robbins J, Chen Z, et al. 2003. Effects of estrogen plus progestin on risk of fracture and bone mineral density: theWomen's Health Initiative randomized trial. JAMA 290:1729-38
52. Greendale GA, Espeland M, Slone S, et al. 2002. Bone mass response to discontinuation of long-Term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. Arch. Intern. Med. 162:665-72
53. Ettinger B, Black DM, Mitlak BH, et al. [Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.] 1999. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637-45
54. Russell RG, Watts NB, Ebetino FH, Rogers MJ. 2008. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos. Int. 19:733-59
55. Black DM, Cummings SR, Karpf DB, et al. 1996. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-41
56. Cummings SR, Black DM, Thompson DE, et al. 1998. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077-82
57. Harris ST, Watts NB, Genant HK, et al. [Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.] 1999. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344-52
58. Black DM, Schwartz AV, Ensrud KE, et al. 2006. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trial. JAMA 296:2927-38
59. Black DM, Reid IR, Boonen S, et al. 2012. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J. Bone Miner. Res. 27:243-54
60. Felsenberg D, Miller P, Armbrecht G, et al. 2005. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone 37:651-54
61. Black DM, ThompsonDE, BauerDC, et al. 2000. Fracture risk reduction with alendronate in womenwith osteoporosis: the Fracture Intervention Trial. FIT ResearchGroup. J. Clin. Endocrinol. Metab. 85:4118-24
62. Liberman UA, Weiss SR, Broll J, et al. 1995. Effect of oral alendronate on bonemineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N. Engl. J. Med. 333:1437-43
63. Cranney A, Wells GA, Yetisir E, et al. 2009. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos. Int. 20:291-97
64. BlackDM, DelmasPD, EastellR, et al. 2007. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356:1809-22
65. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. 2007. Zoledronic acid and clinical fractures and mortality after hip fracture. N. Engl. J. Med. 357:1799-809
66. Khosla S, Burr D, Cauley J, et al. 2007. Bisphosphonate-Associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 22:1479-91
67. Shane E, Burr D, Abrahamsen B, et al. 2014. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 29:1-23
68. Kim SY, Schneeweiss S, Katz JN, et al. 2011. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J. Bone Miner. Res. 26:993-1001
69. Vestergaard P, Schwartz F, Rejnmark L, Mosekilde L. 2011. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos. Int. 22:993-1001
70. Black DM, Kelly MP, Genant HK, et al. 2010. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N. Engl. J. Med. 362:1761-71
71. Abrahamsen B, Eiken P, Eastell R. 2010. Cumulative alendronate dose and the long-Term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J. Clin. Endocrinol. Metab. 95:5258-65
72. Giusti A, Hamdy NA, Papapoulos SE. 2010. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 47:169-80
73. Lenart BA, Neviaser AS, Lyman S, et al. 2009. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos. Int. 20:1353-62
74. Wang Z, Bhattacharyya T. 2011. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J. Bone Miner. Res. 26:553-60
75. Black DM, Bauer DC, Schwartz AV, et al. 2012. Continuing bisphosphonate treatment for osteoporosis-for whom and for how long?. N. Engl. J. Med. 366:2051-53
76. Sambrook PN, Cameron ID, Chen JS, et al. 2011. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos. Int. 22:2551-56
77. Beaupre LA, Morrish DW, Hanley DA, et al. 2011. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos. Int. 22:983-91
78. Cummings SR, San Martin J, McClung MR, et al. 2009. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361:756-65
79. Kong YY, Yoshida H, Sarosi I, et al. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-23
80. Wong BR, Josien R, Lee SY, et al. 1997. TRANCE (tumor necrosis factor [TNF]-related activationinduced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cellspecific survival factor. J. Exp. Med. 186:2075-80
81. Watts NB, Roux C, Modlin JF, et al. 2012. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?. Osteoporos. Int. 23:327-37
82. Papapoulos S, Chapurlat R, Libanati C, et al. 2012. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J. Bone Miner. Res. 27:694-701
83. Bone HG, Bolognese MA, Yuen CK, et al. 2011. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J. Clin. Endocrinol. Metab. 96:972-80
84. McCloskey EV, JohanssonH, Oden A, et al. 2012. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J. Bone Miner. Res. 27:1480-86
85. Neer RM, Arnaud CD, Zanchetta JR, et al. 2001. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344:1434-41
86. Chen P, Miller PD, Delmas PD, et al. 2006. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-Treated postmenopausal women with osteoporosis. J. Bone Miner. Res. 21:1785-90
87. Gallagher JC, Rosen CJ, Chen P, et al. 2006. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Bone 39:1268-75
88. Cosman F, Eriksen EF, Recknor C, et al. 2011. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J. Bone Miner. Res. 26:503-11
89. Finkelstein JS, Wyland JJ, Lee H, Neer RM. 2010. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 95:1838-45
90. SchaferAL, Sellmeyer DE, PalermoL, et al. 2012. Sixmonths of parathyroid hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial. J. Clin. Endocrinol. Metab. 97:3522-29
91. Black DM, Bilezikian JP, Ensrud KE, et al. 2005. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N. Engl. J. Med. 353:555-65
92. Tsai JN, Uihlein AV, Lee H, et al. 2013. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 382:50-56
93. Tsai JN, Uihlein AV, Lee H, et al. 2013. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 6;382(9886):50-56
94. Tsai JC, Uihlein AV, Zhu Y, et al. 2014. Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density and microarchitecture: the DATA-HRpQCT Study. J. Bone Miner. Res. In press
95. Muschitz C, Kocijan R, Fahrleitner-Pammer A, et al. 2013. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density. J. Bone Miner. Res. 28:196-205
96. Bockman RS, Nielsen E, Huang W. 2013. Early bone resorptive response to teriparatide predicts bone density outcome at 2 years. Presentation No. SA0375. Poster presented at Annu.Meet. Am. Soc. Bone Miner. Res., Baltimore, MD
97. McClungMR, Grauer A, Boonen S, et al. 2014. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370:412-20
98. Austin M, Yang YC, Vittinghoff E, et al. 2012. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J. Bone Miner. Res. 27:687-93
99. Jacques RM, Boonen S, Cosman F, et al. 2012. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with onceyearly zoledronic acid 5mg: theHORIZON-Pivotal FractureTrial (PFT). J. Bone Miner. Res. 27:1627-34
100. Andreopoulou